Dr. Klein has a track record as an executive over more than 20 years in the oncology and biopharmaceutical industry. She is currently on the Board of Directors for Argenx, a dual-listed (Euronext Brussels and NASDAQ), clinical-stage therapeutic antibody company developing novel drugs in severe autoimmune disease. She is also on the Board of Frontier Medicines; Shasqi and ONA Therapeutics She was previously on the Board of Directors of F-Star Therapeutics, Jiya Acquisition Corp, a special purpose acquisition company (SPAC) affiliated with Samsara BioCapital, Sardona and I-MAB. Dr. Klein is the Principal and Founder of PMK BioResearch, which offers strategic consulting in oncology drug development. Other current directorships: Argenx (arGEN-X ADS (NASD)), Argenx (arGENX (EURONEXT), Shasqi. Former directorships (last 3 years): F-star Therapeutics (NASDAQ: FSTX), I-MAB, Sardona, Jiya Acquisition Corp.
